Substrate profiling of Zika virus NS2B-NS3 protease

FEBS Letters

Volumn 590, Issue 20, 2016, Pages 3459-3468

  Gruba, Natalia ^a   Rodriguez Martinez, Jose Ignacio ^b   Grzywa, Renata ^c   Wysocka, Magdalena ^a   Skoreński, Marcin ^c   Burmistrz, Michał ^b   Łęcka, Maria ^c   Lesner, Adam ^a   Sieńczyk, Marcin ^c   Pyrć, Krzysztof ^b  

^a UNIVERSITY OF GDA SK   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

combinatorial chemistry; NS2B NS3 protease; substrate library; substrate mapping; Zika virus

Indexed keywords

NONSTRUCTURAL PROTEIN 2; NS2B PROTEIN; SERINE PROTEASE NS3; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRAL PROTEIN; HYBRID PROTEIN; PEPTIDE LIBRARY; PROTEIN BINDING;

ENZYME SUBSTRATE; FLAVIVIRIDAE; GENE EXPRESSION SYSTEM; GUILLAIN BARRE SYNDROME; LETTER; MICROCEPHALY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; VIRUS REPLICATION; ZIKA FEVER; ZIKA VIRUS; BINDING SITE; CHEMISTRY; ENZYME SPECIFICITY; ENZYMOLOGY; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; METABOLISM; MOLECULAR DOCKING; MOLECULAR MODEL; PEPTIDE LIBRARY; PROCEDURES;

BINDING SITES; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PEPTIDE LIBRARY; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS; SERINE ENDOPEPTIDASES; SUBSTRATE SPECIFICITY; VIRAL NONSTRUCTURAL PROTEINS; ZIKA VIRUS;

EID: 84991607707     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1002/1873-3468.12443     Document Type: Article

References (41)

1. Dick GW, Kitchen SF and Haddow AJ (1952) Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 46, 509–520.
2. Wong PS, Li MZ, Chong CS, Ng LC and Tan CH (2013) Aedes (Stegomyia) albopictus (Skuse): a potential vector of Zika virus in Singapore. PLoS Negl Trop Dis 7, e2348.
3. Bearcroft WG (1956) Zika virus infection experimentally induced in a human volunteer. Trans R Soc Trop Med Hyg 50, 442–448.
4. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, Pretrick M, Marfel M, Holzbauer S, Dubray C et al. (2009) Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med 360, 2536–2543.
5. Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, Mallet HP, Sall AA and Musso D (2016) Guillain-Barre Syndrome outbreak associated with Zika virus infection in French polynesia: a case-control study. Lancet 387, 1531–1539.
6. Dupont-Rouzeyrol M, O'Connor O, Calvez E, Daurès M, John M, Grangeon JP and Gourinat AC (2014) Co-infection with Zika and dengue viruses in 2 patients, New Caledonia. Emerg Infect Dis 21, 381–382.
7. Zanluca C, Melo VC, Mosimann AL, Santos GI, Santos CN and Luz K (2015) First report of autochthonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz 110, 569–572.
8. Campos GS, Bandeira AC and Sardi SI (2015) Zika virus outbreak, Bahia, Brazil. Emerg Infect Dis 21, 1885–1886.
9. Mlakar J, Korva M, Tul N, Popović M, Poljšak-Prijatelj M, Mraz J, Kolenc M, Resman Rus K, Vesnaver Vipotnik T, Fabjan Vodušek V et al. (2016) Zika virus associated with microcephaly. N Engl J Med 374, 951–958.
10. Cugola FR, Fernandes IR, Russo FB, Freitas BC, Dias JL, Guimarães KP, Benazzato C, Almeida N, Pignatari GC, Romero S et al. (2016) The Brazilian Zika virus strain causes birth defects in experimental models. Nature 534, 267–271.
11. Weaver SC, Costa F, Garcia-Blanco MA, Ko AI, Ribeiro GS, Saade G, Shi PY and Vasilakis N (2016) Zika virus: history, emergence, biology, and prospects for control. Antiviral Res 130, 69–80.
12. Lei J, Hansen G, Nitsche C, Klein CD, Zhang L and Hilgenfeld R (2016) Crystal structure of Zika virus NS2B-NS3 protease in complex with a boronate inhibitor. Science 353, 503–505.
13. Morikawa K, Lange CM, Gouttenoire J, Meylan E, Brass V, Penin F and Moradpour D (2011) Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. J Viral Hepat 18, 305–315.
14. Shafee N and AbuBakar S (2003) Dengue virus type 2 NS3 protease and NS2B-NS3 protease precursor induce apoptosis. J Gen Virol 84, 2191–2195.
15. Ramanathan MP, Chambers JA, Pankhong P, Chattergoon M, Attatippaholkun W, Dang K, Shah N and Weiner DB (2006) Host cell killing by the West Nile Virus NS2B-NS3 proteolytic complex: NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway. Virology 345, 56–72.
16. Yu CY, Chang TH, Liang JJ, Chiang RL, Lee YL, Liao CL and Lin YL (2012) Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog 8, e1002780.
17. Bastos Lima A, Behnam MA, El Sherif Y, Nitsche C, Vechi SM and Klein CD (2015) Dual inhibitors of the dengue and West Nile virus NS2B-NS3 proteases: synthesis, biological evaluation and docking studies of novel peptide-hybrids. Bioorg Med Chem 23, 5748–5755.
18. Hammamy MZ, Haase C, Hammami M, Hilgenfeld R and Steinmetzer T (2013) Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease. ChemMedChem 8, 231–241.
19. Behnam MA, Nitsche C, Boldescu V and Klein CD (2016) The medicinal chemistry of Dengue virus. J Med Chem 59, 5622–5649.
20. Timiri AK, Sinha BN and Jayaprakash V (2016) Progress and prospects on DENV protease inhibitors. Eur J Med Chem 117, 125–143.
21. Weigel LF, Nitsche C, Graf D, Bartenschlager R and Klein CD (2015) Phenylalanine and phenylglycine analogues as arginine mimetics in dengue protease inhibitors. J Med Chem 58, 7719–7733.
22. Chappell KJ, Stoermer MJ, Fairlie DP and Young PR (2008) West Nile Virus NS2B/NS3 protease as an antiviral target. Curr Med Chem 15, 2771–2784.
23. Skoreński M and Sieńczyk M (2013) Viral proteases as targets for drug design. Curr Pharm Des 19, 1126–1153.
24. Nall TA, Chappell KJ, Stoermer MJ, Fang NX, Tyndall JD, Young PR and Fairlie DP (2004) Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease. J Biol Chem 279, 48535–48542.
25. Leung D, Schroder K, White H, Fang NX, Stoermer MJ, Abbenante G, Martin JL, Young PR and Fairlie DP (2001) Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J Biol Chem 276, 45762–45771.
26. Yusof R, Clum S, Wetzel M, Murthy HM and Padmanabhan R (2000) Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem 275, 9963–9969.
27. Wysocka M, Gruba N, Grzywa R, Giełdoń A, Bąchor R, Brzozowski K, Sieńczyk M, Dieter J, Szewczuk Z, Rolka K et al. (2016) PEGylated substrates of NSP4 protease: a tool to study protease specificity. Sci Rep 6, 22856.
28. Hojo K, Maeda M, Iguchi S, Smith T, Okamoto H and Kawasaki K (2000) Amino acids and peptides. V. Facile preparation of p-nitroanilide analogs by the solid-phase method. Chem Pharm Bull (Tokyo) 48, 1740–1744.
29. Sole NA and Barany G (1992) Optimization of solid-phase synthesis of [Ala8]-dynorphin-A. J Org Chem 57, 5399–5403.
30. Houghten RA, Pinilla C, Blondelle SE, Appel JR, Dooley CT and Cuervo JH (1991) Generation and use of synthetic peptide combinatorial libraries for basic research and drug discovery. Nature 54, 84–86.
31. Halgren TA (1996) Merck molecular force field. 1. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 17, 490–519.
32. ten Brink T and Exner TE (2010) pK(a) based protonation states and microspecies for protein-ligand docking. J Comput Aided Mol Des 24, 935–942.
33. Korb O, Stutzle T and Exner TE (2009) Empirical scoring functions for advanced protein-ligand docking with PLANTS. J Chem Inf Model 49, 84–96.
34. Assenberg R, Mastrangelo E, Walter TS, Verma A, Milani M, Owens RJ, Stuart DI, Grimes JM and Mancini EJ (2009) Crystal structure of a novel conformational state of the flavivirus NS3 protein: implications for polyprotein processing and viral replication. J Virol 83, 12895–12906.
35. Aleshin AE, Shiryaev SA, Strongin AY and Liddington RC (2007) Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci 16, 795–806.
36. Poulsen A, Kang C and Keller TH (2014) Drug design for flavivirus proteases: what are we missing? Curr Pharm Des 20, 3422–3427.
37. Niyomrattanakit P, Yahorava S, Mutule I, Mutulis F, Petrovska R, Prusis P, Katzenmeier G and Wikberg JE (2006) Probing the substrate specificity of the dengue virus type 2 NS3 serine protease by using internally quenched fluorescent peptides. Biochem J 397, 203–211.
38. Ang MJ, Li Z, Lim HA, Ng FM, Then SW, Wee JL, Joy J, Hill J and Chia CS (2014) A P2 and P3 substrate specificity comparison between the Murray Valley encephalitis and West Nile virus NS2B/NS3 protease using C-terminal agmatine dipeptides. Peptides 52, 49–52.
39. Kurt YN, Swanstrom R and Schiffer CA (2016) Improving viral protease inhibitors to counter drug resistance. Trends Microbiol 24, 547–557.
40. Li J, Lim SP, Beer D, Patel V, Wen D, Tumanut C, Tully DC, Williams JA, Jiricek J, Priestle JP et al. (2005) Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem 280, 28766–28774.
41. Robin G, Chappell K, Stoermer MJ, Hu SH, Young PR, Fairlie DP and Martin JL (2009) Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J Mol Biol 385, 1568–1577.